

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Blueberries Medical Corp. (“Blueberries” or the “Issuer”).

Trading Symbol: BBM

This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.



Blueberries
Medical Corp.

BLUEBERRIES MEDICAL CORP.

(FORMERLY CDN MSOLAR CORP.)

**CONDENSED INTERIM
CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED
MARCH 31, 2021 and 2020**

(EXPRESSED IN CANADIAN DOLLARS)

(UNAUDITED)

Management's Comments on Unaudited Condensed Interim Consolidated Financial Statements

The accompanying unaudited condensed interim consolidated financial statements of Blueberries Medical Corp. (the "Company" or "Blueberries") for the three months ended March 31, 2021, and 2020 have been prepared by the management of Blueberries, reviewed by the Audit Committee of the Board of Directors and approved by the Board of Directors.

In accordance with National Instrument 51-102, Continuous Disclosure Obligations of the Canadian Securities Administrators, the Company herewith discloses that the accompanying unaudited interim consolidated financial statements have not been reviewed by an auditor.

May 31, 2021

"Facundo Garreton"

Facundo Garreton
Chairman & Interim CEO

"Ian D. Atacan"

Ian D. Atacan CPA, CMA
Chief Financial Officer

BLUEBERRIES MEDICAL CORP.
Interim Condensed Consolidated Statements of Financial Position
(unaudited)

		As at March 31,	As at December 31,
(Expressed in Canadian Dollars)	Note Reference	2021	2020
ASSETS			
Current Assets			
Cash and cash equivalents		\$ 990,886	\$ 306,507
Other receivables		98,041	203,987
Prepays		81,331	12,140
		1,170,258	522,634
Non-Current Assets			
Advances towards property plant & equipment	4	1,994,250	1,994,250
Property plant & equipment	5	2,375,997	2,736,986
Right-of-use asset	6	514,724	608,789
Intangible assets	7	786,964	841,335
Investment in joint operation	8	566,218	566,218
Total Assets		\$ 7,408,411	\$ 7,270,212
LIABILITIES AND EQUITY			
Current Liabilities			
Trade accounts payable & accrued liabilities	16	\$ 963,720	\$ 999,050
Current portion of lease liability	6	188,990	208,558
Employee benefits	16	27,390	43,424
Derivative liability	9	845,866	845,866
		2,025,966	2,096,898
Non-Current Liabilities			
Convertible debt	9	899,782	837,293
Long-term lease liability	6	372,175	446,242
Total Liabilities		3,297,923	3,380,433
Equity			
Share capital	10	14,732,388	13,637,620
Warrants	11	1,194,870	4,614,288
Contributed surplus	12	5,815,892	2,486,402
Accumulated other comprehensive loss		(778,701)	(584,895)
Deficit		(16,853,961)	(16,263,636)
Total equity		4,110,488	3,889,779
Total liabilities and equity		\$ 7,408,411	\$ 7,270,212
Going concern	2		
Related party transactions	16		
Commitments	18		

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

On behalf of the Board

"Facundo Garreton"
Facundor Garreton, Chairman

"Catherine Lathwell"
Catherine Lathwell, Chair of Audit Committee

BLUEBERRIES MEDICAL CORP.**Interim Condensed Consolidated Statements of Loss and Comprehensive Loss**

(unaudited)

(Expressed in Canadian Dollars)	Note Reference	Three Months Ended March 31,	
		2021	2020
Revenues			
Product revenues		\$ 23,120	\$ -
Cost of sales		(1,195)	-
Gross profit		\$ 21,925	\$ -
Expenses			
Pre-operating expenses		\$ (114,171)	\$ (251,646)
General and administrative expenses	13	(159,953)	(1,083,299)
Depreciation and amortization	5,6,7	(217,026)	(175,892)
Finance expense	9	(62,489)	-
Foreign exchange loss		(35,266)	(135,470)
Total expenses		(588,905)	(1,646,307)
Other expense			
Other expense		(23,345)	(23,047)
Total other expense		(23,345)	(23,047)
Net loss before income tax		(590,325)	(1,669,354)
Current and deferred income tax		-	-
Net loss		\$ (590,325)	\$ (1,669,354)
Other Comprehensive Loss			
Foreign currency translation adjustment		\$ (193,806)	\$ (174,243)
		(193,806)	(174,243)
Comprehensive loss		\$ (784,131)	\$ (1,843,597)
Net loss per share - basic and diluted	14	(0.004)	(0.013)
Weighted average number of shares	14	139,201,916	123,701,831

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

BLUEBERRIES MEDICAL CORP.

Interim Condensed Consolidated Statements of Changes in Equity

(unaudited)

	Note Reference	Common Shares	Share Capital	Warrants	Contributed Surplus	Accumulated Other Comprehensive Loss	Deficit	Total
<i>(Expressed in Canadian Dollars)</i>								
Balance at December 31, 2020		126,701,831	\$ 13,637,620	4,614,288	2,486,402	(584,895)	(16,263,636)	\$ 3,889,779
Shares issued - private placement	10	15,384,615	\$ 1,000,000					1,000,000
Share issuance costs - private placement	10		(30,000)					(30,000)
Shares issued - exercise of options	10,12	660,000	92,268		(26,268)			66,000
Shares issued - share based compensation	10,12	250,000	32,500					32,500
Stock option expense	12				(63,660)			(63,660)
Warrants expired	11			(3,419,418)	3,419,418			-
Other comprehensive loss						(193,806)		(193,806)
Net loss							(590,325)	(590,325)
Balance at March 31, 2021		142,996,446	\$ 14,732,388	1,194,870	5,815,892	(778,701)	(16,853,961)	\$ 4,110,488
Balance at December 31, 2019		123,701,831	\$ 13,487,620	4,614,288	1,680,488	(383,455)	(11,323,529)	\$ 8,075,412
Stock option expense	12				502,944			502,944
Other comprehensive loss						(174,243)		(174,243)
Net loss							(1,669,354)	(1,669,354)
Balance at March 31, 2020		123,701,831	\$ 13,487,620	4,614,288	2,183,432	(557,698)	(12,992,883)	\$ 6,734,759
Shares issued - purchase of BBV Labs	8,10	3,000,000	\$ 150,000					150,000
Stock option expense	12				302,970			302,970
Other comprehensive loss						(27,197)		(27,197)
Net loss							(3,270,753)	(3,270,753)
Balance at December 31, 2020		126,701,831	\$ 13,637,620	4,614,288	2,486,402	(584,895)	(16,263,636)	\$ 3,889,779

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

BLUEBERRIES MEDICAL CORP.**Interim Condensed Consolidated Statements of Cash Flows**

(unaudited)

		Three Months Ended March 31,	
	Note		
(Expressed in Canadian Dollars)	Reference	2021	2020.
Cash generated from (used in)			
Operating activities			
Net loss		\$ (590,325)	\$ (1,669,354)
Adjustment for:			
Depreciation and amortization	5,6,7	217,026	175,892
Share based compensation	10,12	(31,160)	502,944
Interest on lease, related party debt & decommissioning provision		15,949	20,398
Finance expense	9	62,489	-
Unrealized foreign exchange loss		34,369	136,029
Change in non-cash working capital	15	17,649	78,696
Net cash used in operating activities		(274,003)	(755,395)
Investing activities			
Purchase of property, plant, and equipment	5	-	(188,219)
Purchase of licences		(13,768)	(17,083)
Advances towards property, plant, and equipment	4	-	(2,397)
Net cash used in investing activities		(13,768)	(207,699)
Financing activities			
Principal portion of lease payments	6	(50,073)	(53,450)
Issuance of shares, net of costs	10,12	970,000	-
Options exercised		66,000	-
Net cash generated from (used in) financing activities		985,927	(53,450)
Net cash from operating, investing and financing activities		698,156	(1,016,544)
Effects of exchange rate changes on cash		(13,777)	(39,248)
Cash, beginning of period		306,507	2,666,191
Cash, end of period		990,886	1,610,399
Interest paid in cash		320	-
Interest received in cash		16	5,470
Taxes paid in cash		-	-

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)



1. NATURE OF OPERATIONS

Blueberries Medical Corp. (the "Company", "Blueberries" or "BBM"), is a licensed producer of psychoactive and non-psychoactive cannabis by-products in Colombia.

Blueberries, which formerly operated under the name CDN MSolar Corp. ("CMS"), was incorporated in Canada on March 15, 2013 under the Business Corporations Act (British Columbia). On September 30, 2013, the Company completed an amalgamation with MN Ventures Ltd. ("MN"), a reporting issuer and continued under the name CDN MSolar Corp.

On February 5, 2019, Blueberries completed a transaction (the "Transaction") with Blueberries Cannabis Corp. (the "Private Company" or "BCC"), a private company registered under the Ontario Business Corporations Act. Simultaneously with the Transaction, CMS legally changed its name to Blueberries Medical Corp. Blueberries carries out its operations through the Private Company's wholly owned subsidiary, Blueberries S.A.S ("BBSAS").

References within these financial statements to the "Company" for periods, dates and/or transactions prior to the Transaction are in reference to the Private Company, as the corporate entity of interest pre-Transaction. Alternatively, references within these financial statements to the "Company" for periods, dates and/or transactions subsequent to the Transaction are in reference to Blueberries, as the corporate entity of interest post-Transaction. The comparative periods reflected in these financial statements are those of the Private Company, as the financials are a continuance of BCC.

The Company's corporate office and its principal place of business are 8500 West Georgia Street, Suite 2200, Vancouver, BC, V6C 3E8. On February 6, 2019, the common shares of the Company were listed on the Canadian Securities Exchange (the "CSE") under the symbol "CNSX: BBM". The common shares are also listed on the Frankfurt Stock Exchange ("FSE") under the symbol "10A" and on the OTCQB Market in the United States under the ticker symbol "BBRRF".

2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE

a) Statement of compliance

The unaudited condensed interim consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") and IFRS Interpretations Committee ("IFRIC") interpretations applicable to companies reporting under IFRS, including IAS 34, Interim Financial Reporting and include the operating results of Blueberries and its subsidiaries. Accordingly, certain information and disclosure normally included in annual financial statements prepared in accordance with IFRS have been omitted or condensed. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2020, which were prepared in accordance with IFRS.

These unaudited condensed interim consolidated financial statements as at and for the period ended March 31, 2021 and 2020 were authorized for issuance on May 31, 2021 by the Blueberries Board of Directors.

b) Basis of measurement and going concern

These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to discharge its obligations and realize its assets in the normal course of operations for the foreseeable future. Since incorporation, the Company has incurred a net loss with no revenue-generating operations, which were primarily financed from proceeds received through issuance of share capital. Until the Company's assets start generating cash flow, it will continue to exhaust its remaining financial resources to fund existing operations. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern as it will be contingent upon the Company's ability to successfully identify and procure necessary capital, which may be by way of strategic transactions to obtain financing and/or generate profitable operations that are beneficial to the Company and its shareholders.

Management believes that the going concern assumption is appropriate for these unaudited condensed interim consolidated financial statements and that the Company will be able to meet its budgeted administrative costs during the upcoming year and beyond when considering the Company's current financial forecast. However, there is no certainty as to the timing and likelihood of realizing a strategic transaction that would provide additional financial resources beyond those currently retained by the Company. Should the going concern assumption not be appropriate and the Company is not able to realize its assets and settle its liabilities, these unaudited condensed interim consolidated financial statements would require adjustments to the amounts and classifications of assets and liabilities.

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)



3. SIGNIFICANT ACCOUNTING POLICIES, ACCOUNTING STANDARDS AND AMENDMENTS

The accounting policies adopted are consistent with those of the Company's consolidated financial statements for the year ended December 31, 2020.

4. ADVANCES TOWARDS PROPERTY, PLANT, AND EQUIPMENT

Advances towards property, plant and equipment include \$1,994,250 (US\$1,500,000) that was paid in February 2019 for 15 hectares of farmland in Cogua (Zipaquirá), Colombia. The title on the land has not yet been transferred to the Company. The Company is currently working on the permitting and zoning of the property. The seller of this land is a legal entity whose minority beneficial owner is also a minority shareholder of the Company.

5. PROPERTY, PLANT, AND EQUIPMENT

	Land	Agricultural Facilities	Buildings & Construction	Equipment & Vehicles	Furniture & Fixtures	Total
COST						
Balance, December 31, 2019	2,234	688,706	306,542	1,340,631	16,725	2,354,838
Additions	-	278,962	302,335	234,404	14,421	830,122
Disposals	-	(11,522)	-	-	-	(11,522)
Foreign currency translation	(138)	(5,116)	(2,375)	(75,420)	(900)	(83,949)
Balance, December 31, 2020	2,096	951,030	606,502	1,499,615	30,246	3,089,489
Additions	-	-	-	-	-	-
Disposals	-	-	-	-	-	-
Foreign currency translation	(197)	(89,231)	(56,906)	(140,486)	(2,838)	(289,656)
Balance, March 31, 2021	1,899	861,799	549,596	1,359,129	27,408	2,799,833
ACCUMULATED DEPRECIATION						
Balance, December 31, 2019	-	(23,689)	(17,125)	(17,993)	(1,910)	(60,717)
Depreciation	-	(61,355)	(45,315)	(145,306)	(7,598)	(259,574)
Disposals	-	(11,522)	-	-	-	(11,522)
Foreign currency translation	-	(9,625)	(8,382)	(2,637)	(46)	(20,690)
Balance, December 31, 2020	-	(106,191)	(70,822)	(165,936)	(9,554)	(352,503)
Depreciation	-	(45,627)	(15,995)	(46,238)	(2,487)	(110,348)
Disposals	-	-	-	-	-	-
Foreign currency translation	-	12,537	7,548	17,893	1,037	39,015
Balance, March 31, 2021	-	(139,280)	(79,270)	(194,281)	(11,005)	(423,836)
NET BOOK VALUE						
Net Book Value, December 31, 2019	2,234	665,017	289,417	1,322,638	14,815	2,294,121
Net Book Value, December 31, 2020	2,096	844,839	535,680	1,333,679	20,692	2,736,986
Net Book Value, March 31, 2021	1,899	722,519	470,327	1,164,848	16,403	2,375,997

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

As at March 31, 2021, the Company recognized a lease liability and a corresponding right-of-use asset relating to a leased vehicle and leased extraction facilities in Tocancipa and the rural property in the municipality of Guatavita, Colombia. See Note 18.

Right-of-use asset

Balance, December 31, 2019	823,444
Depreciation	(160,130)
Foreign exchange adjustment	(54,525)
Balance, December 31, 2020	608,789
Depreciation	(39,154)
Foreign exchange adjustment	(54,911)
Balance, March 31, 2021	514,724

⁽¹⁾ The right-of-use asset additions consist of the initial recognition of the lease liability at \$925,990 and estimated dismantlement costs of \$9,294, prior to any interest expense recognized.

⁽²⁾ The right-of-use assets have been depreciated on a straight-line basis over the lease terms.

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)

**6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (continued)**

Long-term lease liability	
Balance, December 31, 2019	618,662
Payments	(204,076)
Interest expense	80,069
Foreign exchange adjustment	(62,126)
Less - current portion	(208,558)
Balance, December 31, 2020	446,242
Payments	(50,073)
Interest expense	23,032
Foreign exchange adjustment	(66,594)
Less - current portion	(188,990)
Balance, March 31, 2021	372,175

7. INTANGIBLE ASSETS

By March 31, 2021, Blueberries S.A.S. was granted licenses to produce, manufacture, market and export cannabis derivatives and products using extracts in Colombia by the Ministry of Health. The licenses obtained for cannabis operations are as follows:

- a license to use seed for planting as well as their export and use for medical and scientific purposes
- a low THC cultivation license (non-psychoactive, less than 1% THC content)
- a production license authorizing the domestic and international distribution of high and low THC Medicinal Cannabis extracts
- a high THC cultivation license (psychoactive, more than 1% THC content)

The fair value attributed to the licenses are straight-line amortized over their estimated useful life of 5 years.

Other finite life intangibles consist of assets such as software related licenses, which are amortized over their estimated useful lives of three years.

A continuity schedule for the balance of the intangible assets is as follows:

Intangible Assets	Total
Balance, December 31, 2019	1,101,427
Additions	34,511
Amortization	(294,035)
Foreign currency translation	(568)
Balance, December 31, 2020	841,335
Additions	13,768
Amortization	(67,622)
Foreign currency translation	(517)
Balance, March 31, 2021	786,964

8. INVESTMENT IN JOINT OPERATION

Blueberries' investment in Argentina (the "Argentina Project") is structured via its 100% ownership of BBV Labs Inc. ("BBV Labs"), a Panamanian company that owns the rights to a joint venture (the "Joint Venture") with an Argentinian state-owned company, Cannabis Avatara, S.E. ("Cannava"), via 75% owned Argentinian operating company, SATIN S.A.S. ("SATIN").

In 2019, Blueberries paid an exclusivity fee to BBV Labs of US\$25,000 (C\$34,258) as reimbursement of expenses incurred in negotiation of the Joint Venture with Cannava.

In 2019, in accordance with the terms of the Joint Venture, Blueberries made an advance of \$381,960 (US\$300,000) to Cannava.

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)



8. INVESTMENT IN JOINT OPERATION (continued)

On November 30, 2020 Blueberries completed the acquisition of BBV Labs, at a purchase price of C\$150,000, and the payment of the purchase price satisfied by Blueberries issuing 3,000,000 common shares in the capital of the Company to the vendors, such common shares to be fair valued at C\$0.05 per common share.

Blueberries' and Cannava's commitments under the Joint Venture are as follows:

- The first phase of the Joint Venture will be a Pilot Cultivation Program (the "Pilot Project").
- Blueberries will build a large-scale modern cultivation facility and processing center of excellence in Argentina.
- Cannava will contribute all licenses/permits and authorizations necessary to import seeds, cultivate, grow, and harvest cannabis, process cannabis, extract cannabis oil and other derivative products, export cannabis and derivative products, and import/export equipment and products.
- Cannava will grant access to utilize 3.2 million ft² (74 acres or 30 hectares) of prime agricultural land for the cultivation and growth of cannabis in Jujuy Province, Argentina.
- Cannava will contribute all cooperation agreements with the National Institute of Agricultural Technology ("INTA"), Ministry of Security, Ministry of Public Health, National Council of Scientific and Technological Investigations ("CONICET") and other regulatory and technological Argentinian authorities as required.

The agreement with Cannava is considered to be a joint operation, however currently only minimal activities have taken place. As of March 31, 2021, the Pilot Project has not yet been implemented and is being developed.

9. CONVERTIBLE DEBT

On July 16, 2020 Blueberries closed a non-brokered private placement offering (the "Offering") of C\$1,000,000 in principal amount of unsecured convertible debentures (the "Debentures"). The Debentures will mature 24 months from the date of closing (the "Maturity Date") and bear interest at a rate of 13% per annum, with an effective interest rate of 32.36%. The Debentures will be convertible at the option of the investors, in whole or in part, into common shares of the Company (the "Shares") at a conversion price of the lower of: (i) C\$0.065 per Share or; (ii) the volume-weighted average price of the Shares on the Canadian Securities Exchange ("CSE") for the 15 consecutive trading day period ending on the conversion date subject to a minimum conversion price of C\$0.05. As the conversion option does not meet the fixed for fixed criteria it has been recorded as a derivative liability.

Prior to the Maturity Date, the Company may prepay all or part of the outstanding principal amount of the Debenture and any accrued and unpaid interest thereon at any time and from time to time, provided that prior to such prepayment, the Company must provide the investors with at least five business days prior notice of such intention to make such prepayment at which time the investors may, but shall not be obligated to, convert any or all of the Debentures in accordance with the terms of the Debentures.

The fair value of the derivative liability was determined using a Monte-Carlo simulation with the following key assumptions at inception and December 31, 2020:

	At inception	At year end
Measurement date	13-Jul-2020	31-Dec-2020
Principal	\$1,000,000	\$1,000,000
Issuance date	13-Jul-2020	13-Jul-2020
Maturity date	13-Jul-2022	13-Jul-2022
Remaining life (years)	2.00	1.53
Interest rate (per year)	13%	13%
Risk free rate (per year)	0.28%	0.22%
Stock price (\$/share)	\$0.05	\$0.10
Conversion price	Lesser of \$0.065 & 15-day VWAP, minimum of \$0.05	

The Company initially recognized \$717,605 as convertible debt liability, and \$270,395 as derivative liability of the conversion feature. Below table shows the continuity of the convertible debt liability and derivative liability.

Fair Value of Derivative Liability

Balance at December 31, 2019	-
Fair value at inception - July 13, 2020	270,395
Unrealized gain on changes in fair value	575,471
Balance, December 31, 2020	845,866
	-
Balance, March 31, 2021	845,866

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)

**9. CONVERTIBLE DEBT (continued)**

Convertible Debt Liability	
Balance at December 31, 2019	-
Amounts issued	1,000,000
Less: Convertible debt issuance cost	(12,000)
Total cash proceeds	988,000
Less: Fair value of derivative liability	(270,395)
Accrued interest	60,667
Accretion	59,021
Balance, December 31, 2020	837,293
Accrued interest	32,500
Accretion	29,989
Balance, March 31, 2021	899,782

10. SHARE CAPITAL

As at March 31, 2021, the Company was authorized to issue unlimited common shares with no par value, with holders of common shares entitled to one vote per share and to dividends, if declared.

Outstanding common shares as of March 31, 2021 are as follows:

	Number of Shares	Amount (\$)
Balance, December 31, 2019	123,701,831	13,487,620
Shares issued to purchase BBV Labs. ⁽¹⁾	3,000,000	150,000
Balance, December 31, 2020	126,701,831	13,637,620
Shares issued from exercise of options ⁽²⁾	660,000	92,268
Share based compensation ⁽³⁾	250,000	32,500
Private placement of common shares ⁽⁴⁾	15,384,615	1,000,000
Share issue costs	-	(30,000)
Balance, March 31, 2021	142,996,446	14,732,388

⁽¹⁾ On November 30, 2020, the Company purchased BBV Labs. in a non-cash transaction, whereby Blueberries issued 3,000,000 common shares at the fair value of \$0.05 per share. No issuance costs were incurred relating to the transaction. See Note 12.

⁽²⁾ During the first quarter of 2021, 660,000 options were exercised at a price of C\$0.10 per share. The shares issued by the Company were allocated to common shares and contributed surplus based on the assessed fair value using the Black-Scholes valuation model.

⁽³⁾ On January 19, 2021, Blueberries issued 250,000 shares to a director of the Company. The issued shares were allocated to common shares at a deemed price of C\$0.13.

⁽⁴⁾ On January 19, 2021, Blueberries completed a non-brokered private placement for aggregate gross proceeds of C\$1,000,000 from the sale of common shares at a price of C\$0.065 per share. As part of the private placement the Company issued 15,384,615 shares. In connection with the private placement, C\$30,000 commissions were paid.

11. WARRANTS

The following table reflects the continuity of warrants for the three months ended March 31, 2021:

	Number of purchase warrants	Number of finder warrants	Total number of warrants
Balance, December 31, 2019	30,666,059	3,454,103	34,120,162
Balance, December 31, 2020	30,666,059	3,454,103	34,120,162
Warrants expired	(16,151,000)	(2,466,100)	(18,617,100)
Balance, March 31, 2021	14,515,059	988,003	15,503,062

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)



11. WARRANTS (continued)

Black-Scholes option pricing model assumptions for warrants

The warrants were allocated a fair value using the Black-Scholes option pricing model with the following assumptions:

	Expiring August 29, 2021		Expiring October 30, 2021	
	Purchase	Finder	Purchase	Finder
Risk-free interest rate	1.40%	1.40%	1.55%	1.55%
Exercise price	\$0.35	\$0.25	\$0.35	\$0.35
Estimated stock price	\$0.24	\$0.24	\$0.14	\$0.14
Expected dividend yield	0%	0%	0%	0%
Expected stock price volatility	85.4%	85.4%	85.3%	85.3%
Expected warrant life	2 years	2 years	2 years	2 years
Fair value of warrant granted	\$0.09	\$0.11	\$0.03	\$0.03

12. STOCK OPTIONS

The following table reflects the continuity of stock options since December 31, 2019:

	Stock options	Weighted average exercise price (C\$)
Balance, December 31, 2019	9,565,000	0.479
Options forfeited ⁽¹⁾	(1,320,000)	0.382
Options issued ⁽²⁾	3,660,000	0.151
Balance, December 31, 2020	11,905,000	0.388
Options forfeited ⁽³⁾	(3,099,998)	0.339
Options exercised ⁽⁴⁾	(660,000)	0.100
Options issued ⁽⁵⁾	2,750,000	0.131
Balance, March 31, 2021	10,895,002	0.355

⁽¹⁾ When an optionee resigns or a contractual relationship with an optionee ends, the stock option plan of Blueberries allows 90 days for vested options to be exercised. During 2020, 1,320,000 unvested options were forfeited resulting in a reversal of stock-based compensation of \$186,446.

⁽²⁾ During the year ended December 31, 2020, 3,660,000 options were granted. 1,000,000 options were granted on January 15, 2020, and 250,000 options were granted on March 19, 2020 all with an exercise price of \$0.25 per option. 2,410,000 options were granted on March 27, 2020 with an exercise price of \$0.10 per option. These options are for a 5-year term, 1,000,000 options expiring in January 2025 and 2,660,000 expiring in March 2025. Of the options 2,743,333 vested immediately, 416,667 will vest in March 2021 and March 2022 and 83,333 will vest in March 2023. Using the Black-Scholes option pricing model, the fair value of the 1,000,000 options granted in January has been estimated at \$0.09, 250,000 options granted on March 19, 2020 has been estimated at \$0.03 and 2,410,000 options granted on March 27, 2020 has been estimated at \$0.04.

⁽³⁾ During the first quarter of 2021, 3,099,998 unvested options were forfeited resulting in a reversal of stock-based compensation of \$251,982.

⁽⁴⁾ During the first quarter of 2021, 660,000 options were exercised at the exercise price of \$0.10 per option.

⁽⁵⁾ On January 19, 2021 and February 3, 2021 Blueberries granted 2,250,000 and 500,000 options to certain directors and managers of the Company to purchase Blueberries' common shares. The options are exercisable at a price of \$0.13 and \$0.135 per option for a 5-year term, expiring on January 19, 2026 and February 3, 2026, respectively, with one-third vesting in January and February 2022, one-third vesting in January and February 2023, and one-third vesting in January and February 2024. The fair values of the options have been estimated at \$0.1095 and \$0.1134, respectively at the grant date using the Black-Scholes option pricing model.

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)

**12. STOCK OPTIONS (continued)****Black-Scholes option pricing model assumptions for stock options**

The stock options were allocated a fair value using the Black-Scholes option pricing model with the following assumptions:

Risk-free interest rate	0.33% - 1.82%
Estimated stock price	\$0.06 - \$0.71
Forfeiture rate	10%
Expected dividend yield	0%
Expected stock price volatility	85.93% - 125.95%
Expected option life	3 - 5 years

The following summarizes stock options issued and outstanding as at March 31, 2021:

Exercise prices (C\$)	Number of options outstanding	Weighted average term to expiry (years)	Number of options exercisable
0.100	1,270,000	3.99	1,270,000
0.130	2,250,000	4.81	-
0.135	500,000	4.85	-
0.250	150,000	3.97	50,000
0.400	2,391,668	2.85	2,116,667
0.550	4,333,334	3.02	3,700,000
0.355	10,895,002	3.56	7,136,667

13. GENERAL AND ADMINISTRATIVE EXPENSES

	Three months ended March 31,	
	2021	2020
Share based compensation	(31,160)	502,944
Marketing and investor relations	-	35,498
Director and management fees	57,000	140,155
Legal	333	43,585
Consulting	17,746	107,063
Salary, wages, and benefits	63,779	150,783
Audit and accounting	(8,817)	22,388
General office	14,808	47,097
Travel	41	10,088
Filing and transfer agent fees	24,902	13,802
Insurance	17,615	4,054
Other	3,705	5,842
Total general and administrative expenses	159,953	1,083,299

14. BASIC AND DILUTED LOSS PER SHARE

For the three months ended March 31, 2021 and 2020, there is no difference between the calculated basic and diluted loss per share. All purchase warrants, finder's warrants, and stock options have been excluded from the calculation as they have an anti-dilutive effect on loss per share.

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)

**15. SUPPLEMENTAL CASHFLOW INFORMATION**

	Three Months ended March 31,	
	2021	2020
Prepays	(70,020)	(39,935)
Other receivables	101,436	(64,913)
Inventory	-	1,715
Trade accounts payable and other accounts payable	(1,092)	194,917
Employee benefits	(12,675)	(13,088)
Change in non-cash working capital	17,649	78,696
Relating to:		
Operating activities	17,649	78,696
Change in non-cash working capital	17,649	78,696

16. RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2021 and 2020, there were separate related party transactions as follows:

- a) During the three months ended March 31, 2021, the Company paid key management personnel, including officers, directors, or their related entities, for management services. For the three months ended March 31, 2021, compensation of key management personnel and directors for services provided was \$177,781 (2020 - \$497,452), including \$104,682 of share-based compensation (2020 - \$321,735). As at March 31, 2021, of the total compensation amounts, \$33,509 was unpaid in accounts payable (2020 - \$51,599). There was \$Nil in employee benefits liabilities at March 31, 2021 (2020 - \$4,090).
- b) Of the C\$1,000,000 convertible debt that were issued on July 16, 2020, C\$814,647 was issued to a company controlled by a director and officer of Blueberries. See Note 9.

17. FINANCIAL INSTRUMENTS

As of March 31, 2021, Blueberries financial instruments consist of cash and cash equivalents, other receivables, trade accounts payable and accrued liabilities, convertible debt, derivative liability, and employee benefits. The fair values of these financial instruments approximate their carrying values due to the short-term maturity of these instruments.

The Company characterizes its fair value measurements of financial instruments into a three-level hierarchy depending on the degree to which the inputs are observable, as follows:

- Level 1 inputs are quoted prices in active markets for identical assets and liabilities;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the assets or liabilities either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability

A financial instrument is classified to the lowest level hierarchy for which a significant input has been used in measuring fair value.

The Company measures cash and cash equivalents and derivative liability at fair value. Cash is classified as Level 1 input in the fair value hierarchy, while the derivative liability is considered as a Level 3 input.

18. COMMITMENTS AND CONTINGENT LIABILITIES

A summary of the Company's commitments as of March 31, 2021 are as follows:

Commitment	2021	2022 and thereafter	Total
Security service agreement	10,321	-	10,321
Consulting and administrative agreements	4,036	-	4,036
Total	14,357	-	14,357

Blueberries Medical Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three months ended March 31, 2021 and 2020
(Expressed in Canadian Dollars)



18. COMMITMENTS AND CONTINGENT LIABILITIES (continued)

In addition to short-term commitments tabled above, the Company has lease liabilities. Details of the leases are as follows. See Note 6.

Leases	Lease Term	Lease Payments			Total
		2021	2022	2023 and after	
Cultivation area (Guatavita - El Recuerdo)	May 21, 2025	-	5,345	-	5,345
Cultivation area (Guatavita)	November 4, 2025	1,440	1,992	6,258	9,690
Vehicle	November 25, 2022	10,005	10,005	-	20,009
Extraction facility (Tocancipa)	October 6, 2024	144,974	193,299	226,009	564,282
Total		156,419	210,641	232,266	599,326

19. GEOGRAPHICAL SEGMENT INFORMATION

The Company is engaged in the growth, cultivation, and development of medicinal cannabis and related products with operations in Colombia. Management has defined the operating segments of the Company based on geographical areas, identifying operations held in Colombia as a separate geographic segment. The Canada segment reflects balances and expenses related to all Company operations in Canada, which collectively represent the corporate operations of the Company.

The following tables show information regarding the Company's segments for the three months ended March 31, 2021 and 2020.

For the three months ended March 31, 2021	Colombia	Canada	Total
Revenues	\$ 23,120	\$ -	\$ 23,120
Cost of Sales	(1,195)	-	(1,195)
Expenses:			
Pre-operating expenses	(114,171)	-	(114,171)
General and administrative expenses	(85,611)	(74,342)	(159,953)
Depreciation and amortization	(152,859)	(64,167)	(217,026)
Finance expense	-	(62,489)	(62,489)
Other expense	(23,313)	(32)	(23,345)
Foreign exchange loss	(35,266)	-	(35,266)
Net Loss	(389,295)	(201,030)	(590,325)
Assets - March 31, 2021	3,424,102	3,984,309	7,408,411
Liabilities - March 31, 2021	912,971	2,384,952	3,297,923

For the three months ended March 31, 2020	Colombia	Canada	Total
Expenses:			
Pre-operating expenses	\$ 251,646	\$ -	\$ 251,646
General and administrative expenses	330,405	752,894	1,083,299
Depreciation and amortization	111,675	64,217	175,892
Other expense (income)	23,218	(171)	23,047
Foreign exchange loss	135,334	136	135,470
Net Loss	852,278	817,076	1,669,354
Assets - March 31, 2020	3,777,103	4,676,558	8,453,661
Liabilities - March 31, 2020	1,097,151	621,751	1,718,902

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
- (b) number and recorded value for shares issued and outstanding,
- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

FACUNDO GARRETON Director & Interim CEO
SEBASTIAN HOCHBAUM Director
PATRICIO VILLALBA Director
CATHERINE LATHWELL Director
IAN ATACAN CFO
JOSE MARIA FERERO President, Latin American Operations

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.



Blueberries
Medical Corp.

BLUEBERRIES MEDICAL CORP.

(Formerly CDN MSolar Corp.)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

**FOR THE THREE MONTHS ENDED
MARCH 31, 2021**

Dated May 31, 2021

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



The following Management's Discussion and Analysis (the "MD&A") of Blueberries Medical Corp. ("Blueberries" or the "Company"), formerly CDN MSolar Corp. ("CMS") for the three months ended March 31, 2021, as well as information and expectations concerning Blueberries' outlook are based on currently available information.

This MD&A should be read in conjunction with Blueberries' unaudited condensed interim consolidated financial statements for the three months ended March 31, 2021, as well as audited annual consolidated financial statements for the year ended December 31, 2020 (collectively, the "Financial Statements"). The Financial Statements and notes thereof are prepared in accordance with International Financial Reporting Standards ("IFRS") and its interpretations adopted by the International Accounting Standards Board ("IASB").

The MD&A, and the annual audited consolidated financial statements have been filed on SEDAR at www.sedar.com. Additional information can also be found on the Company's website at www.blueberriesmed.com.

This MD&A is prepared as of May 31, 2021. All dollar values are expressed in Canadian dollars, unless otherwise indicated.

HIGHLIGHTS

Blueberries is continuing with its previously implemented extensive cost saving measures of reducing administrative, capital, and operational expenditures and preserving working capital to optimize its cost structure and focus on revenue bringing activities.

COVID-19

Starting early 2020, there was a global outbreak of coronavirus disease ("COVID-19"), which has had a significant impact on businesses through the restrictions put in place by the Colombian, Canadian, provincial, and municipal governments regarding travel, business operations and isolation/quarantine orders.

Blueberries continues to closely monitor and respond where possible to the ongoing COVID-19 situation. As the global situation continues to change rapidly, ensuring the well-being of our employees remains one of our top priorities. Our facilities in Colombia remain open and operational with heightened measures in place to protect the health and safety of employees, vendors, partners, and their families. The Company is committed to enhancing these measures and implementing other necessary practices as the situation warrants.

At this time, it is unknown the extent of the impact the COVID-19 outbreak may have on the Company as this will depend on future developments that are highly uncertain and that cannot be predicted with confidence. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease, and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions, and quarantine/isolation measures that are currently, or may be put, in place by Colombia, Canada and other countries to fight the virus. While the extent of the impact is unknown, we anticipate this outbreak may cause reduced customer demand, supply chain disruptions, staff shortages, and increased government regulations, all of which will negatively impact the Company's business and financial condition.

COVID-19 has increased the Company's risk profile significantly, notably due to the following:

- a potential curtailment or total shut down of operations by government
- potential loss of manpower at its facilities
- potential of a Blueberries employee falling ill and causing a disruption to the operations
- the ability to procure and transport critical supplies and parts to the facilities and
- the ability of the Colombian operations to transport finished products to clients to generate revenues.

If any of these events were triggered, the result could be a complete shutdown of the Colombian operations for an undetermined period.

To minimize this risk, the following actions have been taken: a policy has been instituted supporting employees to work from home where practical; preliminary screenings at facilities, any employees or contractors showing potential signs of COVID-19 will be placed into self-isolation; special arrangements at the facilities have been implemented to maximize social distancing.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



The Company is treating the threat of a COVID-19 outbreak very seriously. A care-and-maintenance plan has been prepared and would be executed in the event of an outbreak at one of the facilities.

The Company has entered into a cash preservation mode; all non-critical expenditures have been deferred for the foreseeable future. Should the COVID-19 cause a prolonged interruption of operations, this could impact the Company's ability to secure financing required to progress its strategic initiatives and/or could result in an impairment of asset values.

CORPORATE OVERVIEW AND UPDATE

Blueberries is a fully licensed cannabis producer in Latin America with a focus on cultivating, processing, and supplying medicinal-grade cannabis oil extracts and related products. The common shares of the Company are listed on the Canadian Securities Exchange (the "CSE") under the symbol "CNSX: BBM", in U.S.A on the OTC Markets ("OTC: BBRF") and in Germany on the Frankfurt Bourse ("FRA: 10A").

Blueberries' wholly owned subsidiary, Blueberries SAS ("BBSAS") is a licensed producer and distributor of medicinal cannabis and cannabis-derived products in Colombia.

Colombia Operations

Blueberries' nursery and propagation centers are in the municipality of Guatavita, Cundinamarca region. In Guatavita, Blueberries has upgraded the original facility infrastructure, including irrigation and electrical systems, water reservoirs and propagation facility.

With the Colombian government's resolution of unit of agronomic evaluation issued in 2019, the Company's 142 strains have been registered with the Colombian Agricultural Institute ("ICA"). The Company received approval from the ICA for the registration of five proprietary CBD strains with the national cultivar registry and to commence commercial production of these strains. Additionally, Blueberries has finalized the field tests of its proprietary THC dominant strains and received the approval of five THC strains in October 2020. In April 2021, ICA approved the registration of one of these THC strains, initially for investigation purposes. Approval for commercial purposes is expected soon.

Blueberries currently has 1.3 hectares (140,000 ft²) of open-air greenhouses built, of which approximately 75% is operational. The remaining space will commence operating according to the evolution of the COVID-19 pandemic and global demand.

Blueberries has increased its cannabis cultivation through contract and associate growers to meet market demand for cannabis extracts. The execution of the contract and associate grower model has allowed Blueberries' cultivation to expand by 130% to more than 322,000 ft² (3 hectares) with additional potential expansion of the cultivated land to a total of 1 million ft² (9.2 hectares), with the Cogua land being developed through an ultra-low-cost outdoor cultivation model. The Company is also actively negotiating with local contract growers to further increase its cultivation capacity.

Cannabis crops are currently growing in over 86,000 ft² of open-air greenhouses and outdoor at the Guatavita and Cogua properties. Cultivation, and experimental harvesting are now underway along with additional planting in newly constructed greenhouses. Since mid-2020, a total of 2,221,175 grams of dried flower has been harvested. Yield performance has been in line with expectations and new testing with a pilot batch with different nutrients and conditions has resulted in doubling the clones produced from each "mother" plant.

Initial extraction line with a design capacity to process up to 70,000 kg/year (effective capacity 52,500 kg/year) of dried flower has been put in service, with the objective of becoming an EU-GMP compliant and potentially certified pharma grade extraction operation. The extraction facility is in an industrial park, with capacity to scale up its extraction, processing, and manufacturing capabilities up to six extraction lines. At the extraction facility, Blueberries has developed diverse CBD dominant formulations and commenced stability tests to measure the shelf life of the extracts and finished products. Four of Blueberries' formulations have been approved by the Colombian National Food and Drug Surveillance Institute (Instituto Nacional de Vigilancia de Medicamentos y Alimentos, "INVIMA"), and will be commercialized as master formulas.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Currently cannabis harvested by several contract and associated growers are being processed in the Company's extraction facility under a tolling agreement.

Cogua Property

Acquired by the Company in February 2019, the Cogua property is a 37-acre (15 hectares) agricultural land in the Bogota Savannah. The Cogua property consists of fertile land ideally located approximately 24km from the Company's existing 430,000 ft² (4 hectares) Guatavita production facility and 25km from the Company's state-of-the-art extraction facility. The Cogua property has ideal growing conditions to cultivate consistent, high quality dried flower. There is supply of natural spring water and the area's abundant access to natural sunlight is expected to result in electricity costs that are significantly below market. On April 17, 2020, the Ministry of Justice and Law of the Republic of Colombia granted to Blueberries a non-psychoactive cultivation license for the Cogua property, making it the Company's second licensed cultivation facility to grow non-psychoactive cannabis in Colombia.

The legal boundaries of the 15 hectares land are undefined due to permitting and zoning issues, as the 15 hectares are part of a greater 82 hectares property. After trying to transfer the title of the 15 hectares land for more than 18 months, because of Colombian tax laws, the title transfer of the land has not been proven to be practically possible; therefore, the board of directors of Blueberries has approved the Company to enter a partnership with the landowner to acquire a minority interest in the land ownership company in Cogua. The partnership will be in the form of a share purchase agreement to acquire the Company's already paid interest, so no cash will be exchanged for the transaction. The owner of the 82 hectares land is a legal entity whose minority beneficial owner is also a minority shareholder of the Company.

Medicinal Cannabis Products and Education Programs

On February 13, 2019, Blueberries entered into a letter of intent for a joint venture with Harmony and Life SAS, operating as "El Manantial" medical centers. The joint venture will further the development and commercialization of Blueberries' medicinal cannabis products through El Manantial's rapidly growing patient base and collaboration with El Manantial's team of physicians, pharmacists, and technicians with deep expertise in a variety of medical areas. It will also provide a direct distribution channel to an established and rapidly growing patient base by selling exclusively Blueberries' cannabis-derived products.

In early 2020, Blueberries and El Manantial developed a treatment-focused medical education program designed to assist physicians in prescribing cannabis-based treatments to patients. The magistral formulations which are treatments with custom-designed concentrations and properties, will be prescribed to patients by physicians for the treatment of specific medication conditions.

Blueberries has also partnerships with the Van Uden International Center for Alternative Medicine ("Van Uden") and the Juan N. Corpas University Foundation (the "Foundation"), two renowned Colombian organizations in the health and academic fields.

The Company's partnerships with the Van Uden International Center for Alternative Medicine and El Manantial Medical Centers will allow for commercial distribution of Blueberries products and magistral formulations through a growing combined patient network of over 19,000 patients which is expected to grow to over 60,000 patients over the next 36-month period as four new centers are projected to come online.

Since April 2019, Blueberries has been cooperating with the International Research Center on Cannabis and Mental Health ("IRCCMH") and the Juan N. Corpas University for the development of medical education programs for physicians and patients in Latin America and product formulation.

IRCCMH is a leading research and academic organization in the cannabis sector with extensive experience in cannabis research and education, pharmacology, product formulation and the efficacy of cannabis-based treatments. Based in New York and aligned with the Silver School of Social Work at New York University, IRCCMH is comprised of renowned scientists, educators and clinicians and was created to bridge a gap between research and clinical practice. IRCCMH also creates education programs for physicians and patients and acts as advisor to several state-sponsored medical cannabis programs and has guided state regulators to create and implement cannabis programs in Pennsylvania, Delaware, New Jersey, Utah, California and other states.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Cosmetics

Blueberries' five approved CBD cosmetics products include face cream, lip balm, body cream, beauty balm, and cannabis oil shampoo. Formulation, branding, and packaging for Blueberries' CBD cosmetic products has been finalized and the pilot lot of products have been manufactured at a laboratory. In early October 2019, Blueberries CBD cosmetics were introduced to participants at a sector conference in Bogota. In July 2020, Blueberries signed an agreement with Netshop Fulfillment SAS ("Netshop"), transferring the management of the CBD cosmetics business to Netshop on a temporary basis. In early 2021 the agreement with Netshop was terminated. Blueberries is currently exploring new go-to-market alternatives for the Cosmetics line.

Non-alcoholic Cannabis-based Beverage

This project has been put on hold pending the projected amendment to the Decree 613, which will potentially include regulations to produce beverages and dietary supplements with hemp and CBD in Colombia.

Argentina Project

Blueberries' investment in Argentina (the "Argentina Project") is structured via its 100% ownership of BBV Labs, a Panamanian company that owns 75% of the rights to a joint venture (the "Joint Venture") with an Argentinian state-owned company, Cannabis Avatara, S.E. ("Cannava").

Joint Venture Highlights:

- The rights to cannabis licenses in Argentina acquired by Blueberries are amongst very few such agreements currently in place to supply cannabis products to the Argentinian population exceeding 44 million people. The acquisition also expands the Company's production footprint internationally and may provide additional export opportunities to other countries with evolving cannabis regulations.
- Blueberries to build a large-scale modern cultivation facility and processing center of excellence in Argentina.
- Cannava will contribute all licenses/permits and authorizations necessary to import seeds, cultivate, grow and harvest cannabis, process cannabis, extract cannabis oil and other derivative products, export cannabis and derivative products, and import/export equipment and products.
- Cannava will grant access to utilize 3.2 million ft² (74 acres or 30 hectares) of prime agricultural land for the cultivation and growth of cannabis in Jujuy Province, Argentina, ideally situated in an area with robust modern infrastructure including fresh water, modern power supply and a nearby airport, with additional land available for potential future expansion.
- Cannava will contribute all cooperation agreements with the National Institute of Agricultural Technology (INTA), Ministry of Security, Ministry of Public Health, National Council of Scientific and Technological Investigations (CONICET) and other regulatory and technological Argentinian authorities as required.

The first phase of the Joint Venture project will be a Pilot Cultivation Program (the "Pilot Project") with an estimated capital requirement of \$750,00 to \$1,000,000 and consists of the preparation and cultivation of cannabis on a 50,000 ft² (0.46 hectare) area on public lands provided by Cannava with the goal of producing 4 million grams (4,000 kg) of dry cannabis flower. The Pilot Project will also evaluate and characterize cannabis seeds and strains that are ideal for the climate conditions of Jujuy, and document the proposed operating procedures, technical processes, strains and products that the Joint Venture is seeking to produce.

Historical Developments:

On March 25, 2019, in accordance with the terms of the Joint Venture, Blueberries made an advance of \$300,000 USD to Cannava.

On November 30, 2020, Blueberries closed the purchase of BBV Labs at a purchase price of C\$150,000. Payment of the Purchase Price was satisfied by Blueberries issuing 3,000,000 common shares in the capital of the Blueberries on the closing date to the vendors, such common shares issued at the fair price of CAN\$0.05 per common share.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Blueberries' board of directors, mainly consisting of strategic investors from Argentina, is following the new fast-moving regulations in Argentina and updating the plan of the Pilot Project with the objective of optimizing its investment.

Production Licenses

The legalization of the cultivation of cannabis as medicinal Cannabis was based on Law 1787 of 2016 enacted by Colombian Congress, Decree 613 of 2017 the ("Decree") and regulatory resolutions (577, 578 and 579 of August 8, 2017 enacted by the Ministry of Justice and resolutions 2891 and 2892 of 2017 enacted by the Ministry of Health) which formed a legal framework that regulates the actions of any company in Colombia working with cannabis for medical and scientific purposes, including the cultivation, production, and domestic and international distribution of cannabis, cannabis seeds, High THC Medicinal Cannabis, and Low THC Medicinal Cannabis extracts.

Decree 613 of 2017 specifically outlines the different types of cannabis licenses and general requirements for issuing these licenses. The new requirements from this Decree to obtain a license include providing certification of land use, shareholder structure information, a farming crop plan and manufacturing projected for five years, and registry of plant cultivars with the ICA. The Decree also outlines that the license holder must inform the Ministry of Justice and the National Narcotics Fund of non-psychoactive seeds that become psychoactive either during agricultural evaluation or seed cultivation. Additionally, the Decree outlines new events for termination of licenses including not obtaining at least one quota for each year of licenses and beginning cultivation or commercialization without the ICA registry of plant cultivars.

The Company obtained licenses to grow, cultivate, distribute locally and internationally medical cannabis with high concentrations of Tetrahydrocannabinol "THC" (>1% THC) and medical cannabis with low concentrations of THC (<1% THC). Below is a summary of the licenses, their function, status and application.

Licenses	Function	Grant Date	Application
Non-psychoactive cannabis cultivation	· Seed production for planting	Mar. 15, 2018	· Less than 1.0% THC Production of low THC extracts · Domestic and international distribution
	· Grain production		
	· Manufacture of derivatives		
	· Scientific purposes	Apr. 17, 2020	· Scientific research and extension to Cogua
Psychoactive cannabis cultivation	· Seed production for planting	Oct. 24, 2018	· Production of more than 1.0% THC and high THC extracts. · Domestic and international distribution
	· Grain production		
	· Manufacture of derivatives		
	· Scientific purposes	Dec. 5, 2019	· Scientific research
Seeds	· Marketing or delivery	Dec. 3, 2019	· Marketing: Buying and selling of seeds
	· Scientific purposes		
Manufacture of cannabis derivatives	· National use	Aug. 17, 2018	· Manufacture, Produce, Commercialize and export psychoactive and non-psychoactive cannabis derivatives
	· Exportation		
	· Scientific Research	Jan. 29, 2020	· Scientific research and extension to extraction

Changes in Colombian Cannabis Regulations

It is expected that soon the Ministry of Health and Social Protection of Colombia is going to publish a modification to Decree 613 of 2017, which is the regulation that guarantees access to cannabis for medical and scientific use. The main changes proposed are related to: actions to improve monitoring and control of cannabis according to international agreements, licensing and quota requirements, especially in fabrication of non-psychoactive derivatives, allowing the export of both psychoactive and non-psychoactive dry flower, new regulations on international trade such as enabling

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



use of duty free zones for production of cannabis derivatives, allowing the use of CBD in multiple other product categories and finally including actions to strengthening small and medium national growers and marketers of medicinal cannabis.

To guarantee the juridical safety, the new Decree will have no retroactive effect, grandfathering existing and previous license holders and applications to be processed under current regulations.

DISCUSSION OF OPERATIONS

Selected Financial Information

The following table summarizes results of operations of the Company for the three months ended March 31, 2021, and 2020.

<i>(Expressed in Canadian Dollars)</i>		Three months ended March 31,	
		2021	2020
Revenues	\$	23,120	\$ -
Cost of sales		(1,195)	-
Gross profit	\$	21,925	\$ -
Expenses			
Pre-operating expenses	\$	(114,171)	\$ (251,646)
General and administrative expenses		(159,953)	(1,083,299)
Depreciation and amortization		(217,026)	(175,892)
Finance expense		(62,489)	-
Other expense		(23,345)	(23,047)
Foreign exchange loss		(35,266)	(135,470)
Current and deferred income tax		-	-
Net loss	\$	(590,325)	\$ (1,669,354)
Other Comprehensive Loss			
Foreign currency translation adjustment		(193,806)	(174,243)
Comprehensive loss	\$	(784,131)	\$ (1,843,597)
Loss per share - basic and diluted	\$	(0.004)	\$ (0.013)

	As at March 31, 2021		As at December 31, 2020	
Total assets	\$	7,408,411	\$	7,270,212
Total liabilities		3,297,923		3,380,433
Total equity		4,110,488		3,889,779

Revenues

Blueberries' commercial operations are still in early stages with introductory sales of cloned cuttings of its cultivars to associate growers. The Company did not have revenues during the three months ended March 31, 2020.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Cost of sales

Cost of sales for the cloned cuttings include direct expenses relating to agricultural operations for propagation including strain management, cost allocated from mother plants, irrigation, nutrients, consumables such as supplements, trays, peat, personnel costs, electricity, and allocation of operational fixed costs.

Since the Company is in early stages of commercial operations, a detailed breakdown and discussion of material costs have been presented below under pre-operating expenses.

Pre-operating expenses

Pre-operating expenses are non-capital expenditures relating to Blueberries' cannabis farming and cultivation operations. During the three months ended March 31, 2021, \$114,171 of pre-operating expenses were incurred (2020 - \$251,646). The expenditures have been broken down by the specific nature of the costs as seen below:

	Three months ended March 31,	
	2021	2020
Salary, wages, benefits	54,151	136,126
Supplies, spare parts and equipment	11,341	24,292
License costs	1,544	1,188
Facilities	16,423	444
Laboratory	2,315	3,385
Consultants	-	17,704
Fuel and oil	673	13,254
Transportation	7,189	6,463
Utilities	9,554	19,012
Other	10,981	29,778
Total pre-operating expenses	114,171	251,646

Salary, wages, and benefits included within pre-operating expenses relate to employee costs associated with operations staff as opposed to corporate or administrative support staff. During the three months ended March 31, 2021, due to COVID-19, the company implemented voluntary salary reductions for personnel in management positions, which is reflected in the lower salary, wages, and benefits expenditures during the period.

General and Administrative ("G&A") Expenses

Total G&A expenses of \$159,953 were incurred for the three months ended March 31, 2021 (2020 - \$1,083,299). The nature of G&A expenses is as follows:

	Three months ended March 31,	
	2021	2020
Share based compensation	(31,160)	502,944
Marketing and investor relations	-	35,498
Director and management fees	57,000	140,155
Legal	333	43,585
Consulting	17,746	107,063
Salary, wages, and benefits	63,779	150,783
Audit and accounting	(8,817)	22,388
General office	14,808	47,097
Travel	41	10,088
Filing and transfer agent fees	24,902	13,802
Insurance	17,615	4,054
Other	3,705	5,842
Total general and administrative expenses	159,953	1,083,299

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Share based compensation

The Company's Stock Option Plan (the "Plan") provides for the issue of stock options to directors, officers, employees, contractors, and consultants, who are all considered related parties to the Company. The Plan provides that stock options may be granted up to a number equal to 10% of the Company's outstanding shares. The Plan also indicates that the maximum number of shares which may be issued to any one insider and his or her associates under the Plan, together with any other previously established or proposed share compensation arrangements, within a one-year period shall be 5% of the shares outstanding at the time of the grant. Vesting and other terms and conditions are determined by the Board of Directors at the time they are granted. When an optionee resigns or a contractual relationship with an optionee ends, the Plan allows 90 days for vested options to be exercised. During the first quarter of 2021, 3,099,998 unvested options were forfeited resulting in a reversal of stock-based compensation of \$251,982. After the reversal, the non-cash stock-based compensation for the three months ended March 31, 2021, was a net gain of \$31,160 (2020 – expense of \$502,944). The entire amount has been expensed in the income statement of the Company.

Marketing and investor relations

During the three months ended March 31, 2021, the Company incurred \$Nil (2020 - \$35,498) in marketing and investor relations expenses. The 2020 costs were incurred relating to promotion of Blueberries stock and communication with investors as part of investor relations. These costs were considered necessary in order to help promote the Company, raise capital, and included other business initiatives towards promotion, development, and growth of the Company's operations and assets outside the normal course of the Company's day-to-day endeavors.

Director and management fees

During the three months ended March 31, 2021, the Company incurred \$57,000 in director and management fees (2020 - \$140,155). These are costs incurred specifically for certain directors and officers of the Company for services provided to Blueberries either from themselves personally or through a related entity. The year-on-year decrease reflects savings measures implemented due to COVID-19 pandemic, with certain directors and officers leaving the company. The Company continues to manage its costs and focuses its resources on commercial and revenue-generating activities.

Legal fees

The Company incurred \$333 in legal services during the three months ended March 31, 2021 (2020 - \$43,585). The Q1, 2021 legal fees reflect a one-time cash credit of \$24,303 that was recovered from previously unclaimed HST/GST amounts. The fees incurred in 2021 and 2020 mainly relate to procurement of legal services for private placements, ongoing administrative matters and legal counsel regarding the structure and format of potential business ventures the Company is pursuing.

Consulting

Blueberries enters into consulting agreements for advice and assistance on operations, quality management, facility development, financial and technical counsel, human resources services, and regulatory compliance. Consulting agreements are typically no longer than one year and are entered into for the purposes of increasing efficiency and productivity of the Company's operations. During the three months ended March 31, 2021, total consulting fees of \$17,746 were incurred (2020 - \$107,063). The reduction of consulting fees from 2020 to 2021 are due to the Company having incurred start-up related consulting fees in 2020, mainly engagement of new services by the company at the start of the operations on compliance with EU-GMP standards. The 2021 consulting fees are also lower because of savings realized by financial services being internalized.

Salary, wages, and benefits

Salary, wages, and benefits include payroll, training, benefits, and severance costs of employees in Colombia. For the three months ended March 31, 2021, total salary, wages, and benefits were \$63,779 (2020 - \$150,783). The Company continues to manage its costs, including head count and focuses its resources on commercial and revenue-generating activities.

Audit and accounting fees

Audit and accounting fees include cost of audit, accounting and taxation services provided by the Company's external auditor and other third parties. The Q1, 2021 audit and accounting fees reflect a one-time cash credit of \$23,192 that was recovered from previously unclaimed HST/GST amounts.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



General office

General office expenditures were \$14,808 for the three months ended March 31, 2021 (2020 - \$47,097). General office expenses include office and equipment rent, utilities, communication, and cleaning services, which are expensed as incurred. The year-on-year decrease reflects savings measures implemented due to COVID-19 pandemic. Blueberries closed its Toronto and Bogota offices, with significant monthly rental fee savings.

Travel

Travel expenses were \$41 for the three months ended March 31, 2021 (2020 - \$10,088). The decrease is due to tighter cost control on discretionary expenses and the impact of COVID-19 travel restrictions.

Depreciation and Amortization

Depreciation and amortization of Property, Plant, and Equipment ("PP&E") and intangible assets are dependent upon estimated useful life of an asset, which is the period over which an asset is expected to be available for use. PP&E is depreciated through profit and loss over an asset's estimated useful life. Agricultural facilities and equipment are estimated to have useful lives between 3 – 5 years, while buildings are estimated to have useful lives of 10 years. Assets under construction are not subject to depreciation until they are available for use. Indefinite life licenses are not amortized but are tested for impairment annually, whereas finite useful life licenses are amortized through the income statement.

Right-of-use assets are also depreciated on a straight-line basis over the lesser of the asset useful life and the lease term. As of March 31, 2021, the Company had four right-of-use assets two of which were relating to rural property leased and depreciated over a 6-year lease term. The remaining two were leases of the extraction facility and a vehicle, with terms of five and three years, respectively.

During the three months ended March 31, 2021, the Company incurred total depreciation and amortization expenses of \$217,026 (2020 - \$175,892). The increase in 2021 versus 2020 reflects ramping up of operations with capital investments carried out throughout 2020, resulting in higher depreciation and amortization expenses.

Finance Expense

On July 16, 2020, Blueberries closed C\$1,000,000 unsecured convertible debentures (the "Debentures"), maturing 24 months from the date of closing, and bearing interest at a rate of 13% per annum, with an effective interest rate of 32.36%. The finance expense consists of accrued interest of \$32,500 (2020 – \$Nil) on the convertible debenture and the accretion of convertible debt liability of \$29,989 (2020 - \$Nil).

Foreign Exchange

The Company incurred a foreign exchange loss of \$35,266 for the three months ended March 31, 2021 (2020 - \$135,470). The foreign exchange gains and losses are due to fluctuating foreign currency rates causing additional inflow or outflow of working capital required to pay foreign currency transactions. The Company also incurred a currency translation adjustment loss of \$193,806 for the three months ended March 31, 2021 (2020 – 174,243) due to the Colombian subsidiaries' assets and liabilities being translated at the reporting period exchange rate, while revenues, expenses and cash flows are translated at the average exchange rate for the three months ended March 31, 2021.

SELECTED QUARTERLY FINANCIAL INFORMATION

The table below presents the quarterly financial highlights for the last eight quarters.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



	Revenues	Net loss	Net loss per share
2021			
Q1	23,120	(590,325)	(0.013)
2020			
Q4	26,371	(1,408,271)	(0.012)
Q3	34,963	(1,048,398)	(0.008)
Q2	4,644	(814,084)	(0.007)
Q1	-	(1,669,354)	(0.013)
2019			
Q4	-	(1,552,761)	(0.005)
Q3	-	(2,193,973)	(0.019)
Q2	-	(1,649,978)	(0.015)

LIQUIDITY AND CAPITAL RESOURCES

The principal activities of the Company are cultivating, producing, and distributing psychoactive and non-psychoactive cannabis by-products in Colombia. These activities are financed through the completion of equity transactions such as equity offerings. There is no assurance that future equity capital will be available to the Company in the amounts or at the times desired by the Company or on terms that are acceptable to it, if at all. See discussion of common risk factors below.

The Company has negative cash flow from operations and therefore must utilize its current cash reserves, to maintain its capacity to meet ongoing operating activities. The negative cash flows from operations were driven by the fact that the Cannabis business is in the development phase with minimal revenue to positively affect cash flows. Net cash used in operating activities were \$274,003 for the three months ended March 31, 2021 (2020 - \$755,395) and were mainly attributed to paying off outstanding liabilities recorded in accounts payable and ongoing operating and public company activities, which have been expensed in the income statement of the Company. As of March 31, 2021, trade accounts payable and accrued liabilities had a balance of \$963,720 (December 31, 2020 – \$999,050). This balance was classified as a current liability as all amounts are due within 12 months time. As of March 31, 2021, the Company's working capital was negative \$855,708 (December 31, 2020 – negative \$1,574,264).

Net cash used in investing activities were \$13,768 for the three months ended March 31, 2021 (2020 – \$207,699) mainly to purchase of licenses in 2021 and additional property, plant, and extraction equipment in 2020.

On January 19, 2021, Blueberries closed a non-brokered private placement offering for aggregate gross proceeds of C\$1,000,000 from the sale of common shares at a price of C\$0.065 per share.

Net cash generated from financing activities for the three months ended March 31, 2021, totaled \$985,927 (2020 - Net cash used - \$53,450), reflecting the net proceeds of \$970,000 from the non-brokered private placement and exercise of 660,000 options at a price of C\$0.10 per option, which was partially offset by principal portion of lease payments during the year.

The Company's liquidity risk from financial instruments is minimal as excess cash is held in bank accounts with reputable financial institutions.

While the Company has no amount of cash flow from operations, management believes that with the cost saving measures implemented, the company will be able to meet its administrative overhead costs in the coming months. The Company will require additional funding to complete its extraction facility post-harvest build-out through development and into production and for working capital as it starts generating revenue. The Company will continue to pursue opportunities to raise additional capital through debt and equity markets to fund its future growth and operating activities. Although the Company has been successful in raising funds to date, there can be no assurance that adequate funding will be available in the future, or under terms favourable to the Company. Should the COVID-19 cause a prolonged interruption of global markets, this could impact the Company's ability to secure financing required to progress in building out the extraction facility and/or could result in an impairment of asset values.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



MANAGEMENT OF CAPITAL

The Company's objectives when managing capital are to ensure the Company will have sufficient financial capacity, liquidity, and flexibility to fund the Company's operations, growth, and ongoing developmental activities. The Company is dependent upon funding these activities through a combination of available cash, debt, and equity, which it considers to be the components of its capital structure as outlined below.

	March 31, 2021	December 31, 2020
Shareholders' equity	4,110,488	3,889,779
Cash	990,886	306,507
Working capital, excluding cash	(1,846,594)	(1,880,771)

OFF-BALANCE-SHEET ARRANGEMENTS

As of the date of this MD&A, the Company does not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on the financial performance or financial condition of the Company, including, and without limitation, such considerations as liquidity and capital resources.

OUTSTANDING SHARE DATA

As at the date of this MD&A, the outstanding common shares, stock options, warrants and convertible debt are as follows:

Common shares outstanding	142,996,446
Stock options	10,895,002
Purchaser warrants	14,515,059
Finder warrants	988,003
Convertible debt	16,814,752
Fully diluted shares outstanding	186,209,262

FINANCIAL RISK MANAGEMENT

The Company has exposure to the following risks from its use of financial instruments:

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient cash resources in order to finance operations, fund capital expenditures, and to repay debt and other liabilities of the Company as they come due, without incurring unacceptable losses or risking harm to the Company's reputation.

As of March 31, 2021, the Company's financial liabilities consist of trade accounts payable and accrued liabilities, employee benefits and lease liability, which have contractual payment obligations within one year. The Company manages its liquidity risk by reviewing its capital requirements on an ongoing basis. Based on the Company's working capital position on March 31, 2021, management regards liquidity risk to be high.

Credit risk

Credit risk is the risk of loss associated with the counterparty's inability to fulfil its contractual obligations. Financial instruments subject to credit risk include cash and cash equivalents, and other receivables. All of the Company's cash and short-term investments are held at reputable financial institutions. Other receivables consist mainly of harmonized sales tax and general sales tax receivables that the Company expects to receive from the Government of Canada. As such credit risk is deemed to be low.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Market risk

Market risk is the risk or uncertainty that changes in price, foreign exchange rates, and interest rates will affect the Company's net earnings and the value of financial instruments. Blueberries is exposed to two types of market risk, being foreign currency risk and interest rate risk as outlined below.

Foreign currency risk

Foreign currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Company's functional and reporting currency is the Canadian dollar. However, some of the Company's business transactions and commitments occur in currencies other than Canadian dollars. The Colombian subsidiaries incur expenditures in Colombian pesos, which is their functional currency. Therefore, the Company is exposed to the risk of fluctuations in foreign exchange rates between Colombian pesos and Canadian dollars. Blueberries does not anticipate a significant impact on its condensed interim consolidated financial statements as a result of a 5% change in the exchange rate between the two currencies.

Interest rate risk

Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in prevailing market interest rates. The Company is exposed to interest rate risk on cash and cash equivalents. As at March 31, 2021, the company does not have any promissory notes, or flexible rate debt, as such, fluctuations of interest rates would not have had a significant impact on the condensed interim consolidated financial statements.

Capital risk management

The Company's objectives when managing capital are to ensure the Company will have sufficient financial capacity, liquidity, and flexibility to fund the Company's operations, growth, and ongoing developmental activities. The Company is dependent upon funding these activities through a combination of available cash, debt and equity, which it considers to be the components of its capital structure as outlined below.

RELATED PARTY TRANSACTIONS

The Company lists its related party transactions in Note 16 of its unaudited condensed consolidated interim financial statements for the three months ended March 31, 2021.

BUSINESS RISKS

COVID-19

Early 2020, the World Health Organization declared the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", a pandemic resulting in worldwide emergency measures to combat the spread of the virus. These measures, which include self-quarantine period, have caused disruption to businesses globally, which are resulting in an economic slowdown and uncertainties potentially affecting the Company's cash flows, financial condition and results of operations. It is not possible to reliably estimate the length or effect of these developments due to uncertainties including the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and actions that may be taken by governmental authorities and central banks to contain COVID-19 or to treat its impact.

Limited Operating History

Blueberries is an early-stage company and has a limited operating history upon which its business and future prospects may be evaluated. Blueberries will be subject to all of the business risks and uncertainties associated with any new business enterprise, including the risk that it will not achieve its operating goals. In order for Blueberries to meet future operating and debt service requirements, Blueberries will need to be successful in its growing, marketing and sales efforts. Additionally, where Blueberries experiences increased sales, Blueberries' current operational infrastructure may require changes to scale the Company's business efficiently and effectively to keep pace with demand and achieve long-term profitability, including the possibility to upgrade the operation to be compliant with EU-GMP pharma grade certification. If Blueberries' new products and services are not accepted by new customers, the Company's operating results may be materially and adversely affected.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Managing Growth

In order to manage growth and change in strategy effectively, the Company must (i) maintain adequate systems to meet customer demand; (ii) expand sales and marketing, distribution capabilities and administrative functions; (iii) expand the skills and capabilities of its current management team; and (iv) attract and retain qualified employees. While it intends to focus on managing its costs and expenses over the long term, Blueberries expects to invest to support its growth and may have additional unexpected costs. It may not be able to expand quickly enough to exploit potential market opportunities.

Retention and Acquisition of Skilled Personnel

The loss of any member of the Company's management team, could have a material adverse effect on its business and results of operations. In addition, an inability to hire, or the increased costs of new personnel, including members of executive management, could have a material adverse effect on the Company's business and operating results. At present and for the near future, Blueberries will depend upon a relatively small number of employees to develop, market, sell and support its products. The expansion of marketing and sales of its products will require Blueberries to find, hire and retain additional capable employees who can understand, explain, market and sell its products. There is intense competition for capable personnel in all of these areas and Blueberries may not be successful in attracting, training, integrating, motivating, or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take significant time before they achieve full productivity. As a result, the Company may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses related to equity awards, and may lose new employees to its competitors or other companies before it realizes the benefit of its investment in recruiting and training them. In addition, as the Company moves into new jurisdictions, it will need to attract and recruit skilled employees in those areas.

Legal Proceedings

From time to time, Blueberries may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. Blueberries will evaluate its exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with generally accepted accounting principles. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management's evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on Blueberries' financial results.

Regulatory Compliance Risks

Achievement of Blueberries' business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. Blueberries may not be able to obtain or maintain the necessary licenses, permits, quotas, authorizations or accreditations, or may only be able to do so at great cost, to operate its business. Blueberries cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by local governmental authorities. The impact of the compliance regime, any delays in obtaining, or failure to obtain or keep the regulatory approvals may significantly delay or impact the development of markets, products and sales initiatives and could have a material adverse effect on the business, results of operations and financial condition of Blueberries.

The officers and directors of Blueberries must rely, to a great extent, on Blueberries' Colombian legal counsel and local consultants retained by Blueberries in order to keep abreast of material legal, regulatory and governmental developments as they pertain to and affect Blueberries' business operations, and to assist Blueberries with its governmental relations. Blueberries must rely, to some extent, on those members of management and the board who have previous experience working and conducting business in Colombia in order to enhance its understanding of and appreciation for the local business culture and practices in Colombia.

Blueberries also relies on the advice of local experts and professionals in connection with current and new regulations that develop in respect of banking, financing and tax matters in Colombia. Any developments or changes in such legal, regulatory or governmental requirements or in local business practices in Colombia are beyond the control of Blueberries and may adversely affect its business.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Blueberries will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. Blueberries may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to Blueberries' operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of Blueberries.

Canadian Regulatory and Civil Proceedings

The sale and distribution of cannabis products for medicinal use by licensed producers is legal in certain Canadian provinces. The Canadian federal government legalized marijuana effective October 17, 2018.

Blueberries operates in Colombia pursuant to the Blueberries Licenses and authorizations granted by the Ministry of Justice and the Ministry of Health. Consequently, certain activities conducted by Blueberries are permissible under one regulatory regime while not under another. In the past, Canadian courts and regulatory authorities have taken the view that it is not contrary to Canadian federal or provincial law for a person to be engaged in, or for an entity to hold interests in affiliates that are engaged in, certain regulated activities where such activities may be regulated differently than in the home jurisdictions and have enforced extra-territorial laws even where such laws (or regulatory regimes applicable to certain activities or industries) differs from those in the Canadian jurisdiction. There is a risk however that the Canadian courts or applicable Canadian or other governmental authorities may take a contrary view with respect to the business of Blueberries and view Blueberries as having violated their local laws, despite Blueberries having obtained all applicable Colombian licenses or authorizations and despite that Blueberries does not carry on business in Canada. Therefore, there is a risk that civil and criminal proceedings, including class actions, could be initiated against Blueberries. Such potential proceedings could involve substantial litigation expense, penalties, fines, seizure of assets, injunctions or other restrictions being imposed upon Blueberries or its business partners, while diverting the attention of key executives. Such proceedings could have a material adverse effect on Blueberries' business, revenues, operating results and financial condition as well as impact upon Blueberries' reputation.

Change of Cannabis Laws, Regulations and Guidelines

Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require Blueberries to incur substantial costs associated with compliance or alter certain aspects of its business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain aspects of Blueberries' businesses. Blueberries cannot predict the nature of any future laws, regulations, interpretations or applications, nor can it determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on Blueberries' business. Management expects that the legislative and regulatory environment in the cannabis industry in Colombia and internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on Blueberries' business, financial condition and results of operations.

Public opinion can also exert a significant influence over the regulation of the cannabis industry. A negative shift in the public's perception of the cannabis industry could affect future legislation or regulation in different jurisdictions.

Reliance on Blueberries Licenses and Authorizations

Blueberries' ability to grow, store and sell cannabis in Colombia is dependent on Blueberries' ability to sustain and/or obtain the necessary licenses and authorizations by certain authorities in Colombia.

The pending licenses and authorizations are subject to ongoing compliance and reporting requirements and the ability of Blueberries to obtain, sustain or renew any such licenses and authorizations on acceptable terms is subject to changes in regulations and policies and to the discretion of the applicable authorities or other governmental agencies in foreign jurisdictions. Failure to comply with the requirements of the licenses or authorizations or any failure to maintain the licenses or authorizations would have a material adverse impact on the business, financial condition and operating results of Blueberries.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Although Blueberries believes that it will meet the requirements to obtain, sustain or renew the necessary licenses and authorizations, there can be no guarantee that the applicable authorities will issue these licenses or authorizations. Should the authorities fail to issue the necessary licenses or authorizations, Blueberries may be curtailed or prohibited from the production and/or distribution of cannabis or from proceeding with the development of its operations as currently proposed and the business, financial condition and results of the operation of Blueberries may be materially adversely affected.

Reliance on One Facility

The cultivation facility is currently only licensed facility under the Licenses. The Licenses held by Blueberries are specific to the Cultivation Facility. Adverse changes or developments affecting the cultivation facility, including but not limited to a breach of security, could have a material and adverse effect on Blueberries' business, financial condition and prospects. Any breach of the security measures and other facility requirements, including any failure to comply with recommendations or requirements arising from inspections by Colombian regulatory authorities, could have an impact on Blueberries' ability to receive or hold the licenses.

Certain contemplated capital expenditures of Blueberries may require approval of Colombian regulatory authorities. There is no guarantee that Colombian Regulatory Authorities will approve any contemplated expansion and/or renovation, which could adversely affect the business, financial condition and results of Blueberries' operations.

Unexpected disruptions affecting operations, whether due to labor disruptions, supply disruptions, power disruptions, damage to equipment or otherwise

Blueberries' operations may be disrupted by a variety of risks and hazards that are beyond its control, including, but not limited to, fires, power outages, labour disruptions, supply disruptions, flooding, and the inability to obtain suitable or adequate machinery, equipment or labour as well as other risks involved in the cultivation and production of medicinal cannabis.

Demand for Cannabis and Derivative Products

The legal cannabis industry in Colombia is at an early stage of its development. Consumer perceptions regarding legality, morality, consumption, safety, efficacy and quality of medicinal cannabis are mixed and evolving and can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medicinal cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the medicinal cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for medicinal cannabis and on the business, results of operations, financial condition and cash flows of Blueberries. Further, adverse publicity reports or other media attention regarding cannabis in general or associating the consumption of medicinal cannabis with illness or other negative effects or events, could have such a material adverse effect. Public opinion and support for medicinal cannabis use has traditionally been inconsistent and varies from jurisdiction to jurisdiction. While public opinion and support appears to be rising for legalizing medicinal cannabis, it remains a controversial issue subject to differing opinions surrounding the level of legalization. Blueberries' ability to gain and increase market acceptance of its business may require substantial expenditures on investor relations, strategic relationships and marketing initiatives. There can be no assurance that such initiatives will be successful and their failure may have an adverse effect on Blueberries.

Liability, Enforcement, Complaints, etc.

Blueberries' participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against Blueberries. Litigation, complaints, and enforcement actions involving Blueberries could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on Blueberries' future cash flows, earnings, results of operations and financial condition.

Product Liability

As a distributor of products designed to be ingested by humans, Blueberries faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused damages, loss or injury.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



In addition, the sale of Blueberries' products involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of Blueberries' products alone or in combination with other medications or substances could occur. Blueberries may be subject to various product liability claims, including, among others, that Blueberries' products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. A product liability claim or regulatory action against Blueberries could result in increased costs, could adversely affect Blueberries' reputation with its clients and consumers generally, and could have a material adverse effect on the results of operations and financial condition of Blueberries. There can be no assurances that Blueberries will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of Blueberries' potential products.

Insurance Coverage

Blueberries' production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labour disputes, changes in the legal and regulatory framework applicable to Blueberries and environmental contingencies.

Blueberries is in the process of obtaining additional insurance coverage over Blueberries' growing production and facilities. Blueberries is seeking insurance against a variety of risks, including losses and damages relating to its plants, equipment and buildings. Any insurance that Blueberries is successful in obtaining may only cover part of the losses it may incur and may not cover losses on crops due to drought or floods. Furthermore, certain types of risks may not be covered by the future policies. There is a risk that any claims to be paid by an insurer due to the occurrence of a casualty covered may not be sufficient to compensate Blueberries for all of the damages suffered. Blueberries may not be able to maintain or obtain insurance of the type and amount desired at a reasonable cost. If Blueberries were to incur significant liability for which it were not fully insured, it could have a materially adverse effect on Blueberries' business, financial condition and results of operations.

Ability to Establish and Maintain Bank Accounts

While Blueberries does not anticipate dealing with banking restrictions, there is a risk that banking institutions in countries where Blueberries operates will not accept payments related to the cannabis industry. Such risks could increase costs for Blueberries. In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that Blueberries may be required to seek alternative payment solutions, including but not limited to cryptocurrencies such as Bitcoin. There are risks inherent in cryptocurrencies, most notably its volatility and security issues. If the industry was to move towards alternative payment solutions and accept payments in cryptocurrency Blueberries would have to adopt policies and protocols to manage its volatility and exchange rate risk exposures. Blueberries' inability to manage such risks may adversely affect Blueberries' operations and financial performance.

Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of Blueberries' products are recalled due to an alleged product defect or for any other reason, Blueberries could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. Blueberries may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although Blueberries has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if Blueberries is subject to recall, the image of Blueberries could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for Blueberries' products and could have a material adverse effect on the results of operations and financial condition of Blueberries. Additionally, product recalls may lead to increased scrutiny of Blueberries' operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses and potential legal fees and other expenses.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Risks Inherent in an Agricultural Business

Blueberries' business involves the growing of blueberries with the prospect of growing cannabis in the future. Both of which are agricultural products and grown outdoors. The occurrence of severe adverse weather conditions, especially droughts, hail, floods or frost, is unpredictable and may have a potentially devastating impact on agricultural production and may otherwise adversely affect the supply of cannabis. Adverse weather conditions may be exacerbated by the effects of climate change and may result in the introduction and increased frequency of pests and diseases. The effects of severe adverse weather conditions may reduce Blueberries' yields or require Blueberries to increase its level of investment to maintain yields. Additionally, higher than average temperatures and rainfall can contribute to an increased presence of insects and pests, which could negatively affect crops. Future droughts could reduce the yield and quality of Blueberries' production, which could materially and adversely affect Blueberries' business, financial condition and results of operations.

The occurrence and effects of plant disease, insects and pests can be unpredictable and devastating to agricultural, potentially rendering all or a substantial portion of the affected harvests unsuitable for sale. Even when only a portion of the production is damaged, Blueberries' results of operations could be adversely affected because all or a substantial portion of the production costs may have been incurred. Although some plant diseases are treatable, the cost of treatment can be high and such events could adversely affect Blueberries' operating results and financial condition. Furthermore, if Blueberries fails to control a given plant disease and the production is threatened, Blueberries may be unable to supply its customers, which could adversely affect its business, financial condition and results of operations. There can be no assurance that natural elements will not have a material adverse effect on any such production.

Risks Inherent in Rural Real Estate

The Colombian Constitution protects the right to own private property and related rights acquired in compliance with civil regulations. According to Colombian Constitution, legally acquired private property ownership rights cannot be affected if the owner is in compliance with applicable laws.

Except in the case of public necessity or social interest, subject to due process and the payment of an indemnification, expropriations without just cause or on a discriminatory basis are restricted.

In August 2011, Colombia and Canada entered into a Free Trade Agreement (CCOFTA), which outlines the issue of expropriations in Article 811 as well as dispute settlements in Chapter 21. The Free Trade Agreement provides that Canadian investments in Colombia will be granted fair and equitable treatment with full protection and security and will be accorded no less favorable treatment than Colombia grants to its own investors or investors of any other country. It also provides that an investment will not be expropriated except in a nondiscriminatory manner in accordance with due process of law with prompt and adequate compensation. The expropriation provisions cover both traditional "direct" takings and so-called "indirect" or "creeping" expropriation, which results from a measure or a series of measures by a government that have an effect equivalent to direct expropriation without a formal transfer of title or outright seizure of the investment. An investor-state dispute resolution process is provided for in the event that the investment is not provided the protections set out in the CCOFTA. Through this process, a Canadian investor can challenge a Colombian measure through binding international arbitration instead of relying on the Colombian local courts.

Energy Prices and Supply

Blueberries requires substantial amounts of electric energy and other resources for its harvest activities and transport of cannabis. Blueberries relies upon third parties for its supply of energy resources used in its operations. The prices for and availability of energy resources may be subject to change or curtailment, respectively, due to, among other things, new laws or regulations, imposition of new taxes or tariffs, interruptions in production by suppliers, imposition of restrictions on energy supply by government, worldwide price levels and market conditions. If energy supply is cut for an extended period of time and Blueberries is unable to find replacement sources at comparable prices, or at all, Blueberries' business, financial condition and results of operations would be materially and adversely affected.

Supply of Cannabis Seeds

If for any reason the supply of cannabis seeds is ceased or delayed, Blueberries would have to seek alternate suppliers and obtain all necessary authorization for the new seeds. If replacement seeds cannot be obtained at comparable prices, or at all, or if the necessary authorizations are not obtained, Blueberries' business, financial condition and results of operations would be materially and adversely affected.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Changes in Corporate Structure

Colombian cannabis licenses are granted on a non-transferable, non-exchangeable and non-assignable basis. Any breach of this restriction may give rise to unilateral termination of the license by the governmental authority.

Notwithstanding the above, Colombian laws do not provide for specific regulations or restrictions regarding the effects of a change in control, modification of the corporate structure, issuance of shares, or any changes in holders or final beneficiaries of cannabis licenses.

Colombian legislation gives special attention to the identification and background of the legal representatives of licensees. Licensees must file a declaration of the legality of the proceeds of the legal representatives. Furthermore, Decree 613 of 2017 provides a set of resolutive conditions, which enable the Ministry of Health or the Ministry of Justice, as applicable, to terminate a license if the licensee fails to request the amendment of the license within 30 calendar days following any changes in (i) the legal representation of the licensee; or (ii) the declaration that a legal representative is criminally liable for drug trafficking or related crimes, after having issued the respective license.

Emerging Market Risks

Emerging market investment generally poses a greater degree of risk than investment in more mature market economies because the economies in the developing world are more susceptible to destabilization resulting from domestic and international developments.

All of Blueberries' operations are in Colombia. Colombia has a history of economic instability or crises (such as inflation or recession). While there is no current political instability, and historically there has been no change in laws and regulations, this is subject to change in the future and could adversely affect Blueberries' business, financial condition, and results of operations.

Fluctuations in the Colombian economy and actions adopted by the Government of Colombia have had and may continue to have a significant impact on companies operating in Colombia, including Blueberries. Specifically, Blueberries may be affected by inflation, foreign currency fluctuations, regulatory policies, business, and tax regulations and in general, by the political, social and economic scenarios in Colombia and in other countries that may affect Colombia.

Global economic crises could negatively affect investor confidence in emerging markets or the economies of the principal countries in Latin America, including Colombia. Such events could materially and adversely affect Blueberries' business, financial condition and results of operations.

Global Economy

Financial and securities markets in Colombia are influenced by the economic and market conditions in other countries, including other South American and emerging market countries and other global markets. Although economic conditions in these countries may differ significantly from economic conditions in Colombia, investors' reactions to developments in these other countries, such as the recent developments in the global financial markets, may substantially affect the capital flows into, and the market value of securities of issuers with operations in Colombia.

An economic downturn or volatility could have a material adverse effect on Blueberries' business, financial condition and results of operations. The economy of Colombia, where Blueberries' operations are located, has experienced significant economic uncertainty and volatility during recent years. A weakening of economic conditions could lead to reductions in demand for Blueberries' products. For example, its revenues can be adversely affected by high unemployment and other economic factors. Further, weakened economic conditions or a recession could reduce the amount of income customers are able to spend on Blueberries' products. In addition, as a result of volatile or uncertain economic conditions, Blueberries may experience the negative effects of increased financial pressures on its clients. For instance, Blueberries' business, financial condition and results of operations could be negatively impacted by increased competitive pricing pressure, which could result in Blueberries incurring increased bad debt expense. If Blueberries is not able to timely and appropriately adapt to changes resulting from a weak economic environment, its business, results of operations and financial condition may be materially and adversely affected.

A crisis in other emerging market countries could dampen investor enthusiasm for securities of issuers with South American operations. Financial conditions in Argentina, Brazil or other emerging market countries could negatively

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



impact Colombia's economy in the future. If such fluctuations were to occur, Blueberries' business, financial condition and results of operations could be materially and adversely affected.

CSE Restrictions on Business

As a condition to initially listing on the CSE, the CSE required that Blueberries deliver an undertaking (the "Undertaking") confirming that, while listed on CSE, Blueberries will only conduct the business of the production, sale and distribution of medicinal marijuana in Colombia pursuant to the Licenses and in accordance with applicable law, unless prior approval is obtained from CSE. The Undertaking could have an adverse effect on Blueberries' ability to do business or operate outside of Colombia and on its ability to expand its business into other areas, including the provision of non-medical marijuana in the event that the laws were to change to permit such sales, if Blueberries is still listed on the CSE and remains subject to the Undertaking at such time. The Undertaking may prevent Blueberries from expanding into new areas of business when Blueberries' competitors have no such restrictions. All such restrictions could materially and adversely affect the growth, business, financial condition and results of Blueberries' operations.

Risks Related to Investment in a Colombian Company

Operational Risks

Operations in Colombia are subject to risk due to the potential for social, political, economic, legal and fiscal instability. The government in Colombia faces ongoing problems including but not limited to inflation, unemployment and inequitable income distribution. Colombia is also home to South America's largest and longest running insurgency and large swaths of the countryside are under guerrilla influence. In addition, Colombia experiences narcotics-related violence, a prevalence of kidnapping and extortionist activities and civil unrest in certain areas of the country. Such instability may require Blueberries to suspend operations on its properties. Although Blueberries is not presently aware of any circumstances or facts which may cause the following to occur, other risks may involve matters arising out of the evolving laws and policies in Colombia, any future imposition of special taxes or similar charges, as well as foreign exchange fluctuations and currency convertibility and controls, the unenforceability of contractual rights or the taking or nationalization of property without fair compensation, restrictions on the use of expatriates in Blueberries' operations, or other matters. Blueberries also bears the risk that changes can occur in the government of Colombia and a new government may void or change the laws and regulations that Blueberries is relying upon.

Currently there are no restrictions on the repatriation from Colombia of earnings to foreign entities and Colombia has never imposed such restrictions. However, there can be no assurance that restrictions on repatriation of earnings from Colombia will not be imposed in the future. Exchange control regulations require that any proceeds in foreign currency originated on exports of goods from Colombia (including minerals) be repatriated to Colombia. However, purchase of foreign currency is allowed through any Colombian authorized financial entities for purposes of payments to foreign suppliers, repayment of foreign debt, payment of dividends to foreign stockholders and other foreign expenses.

Inflation in Colombia

Colombia has in the past experienced double-digit rates of inflation. If Colombia experiences substantial inflation in the future, Blueberries' costs in Colombian peso terms will increase significantly, subject to movements in applicable exchange rates. Inflationary pressures may also curtail Blueberries' ability to access global financial markets in the longer term and its ability to fund planned capital expenditures, and could materially adversely affect Blueberries' business, financial condition and results of operations. The Colombian government's response to inflation or other significant macro-economic pressures may include the introduction of policies or other measures that could increase Blueberries' costs, reduce operating margins and materially adversely affect its business, financial condition and results of operations.

Operations in Spanish

As a result of Blueberries conducting its operations in Colombia, the books and records of Blueberries, including key documents such as material contracts and financial documentation are principally negotiated and entered into in the Spanish language and English translations may not exist or be readily available.

Enforcement of Judgments

Blueberries is incorporated under the laws of Canada; however all of its assets are located outside Canada. Furthermore, many of Blueberries' directors and officers reside outside Canada. As a result, investors may not be able to effect service of process within Canada upon Blueberries' directors or officers or enforce against them in Canadian

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



courts judgments predicated on Canadian securities laws. Likewise, it may also be difficult for an investor to enforce in Canadian courts judgments obtained against these persons in courts located in jurisdictions outside Canada.

As a result of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the Board or controlling shareholders than they would as public shareholders of a Canadian company.

Financial and Accounting Risks

Access to Capital

In executing its business plan, Blueberries makes, and will continue to make, substantial investments and other expenditures related to acquisitions, research and development and marketing initiatives. Since its incorporation, Blueberries has financed these expenditures through offerings of its equity securities. Blueberries will have further capital requirements and other expenditures as it proceeds to expand its business or take advantage of opportunities for acquisitions or other business opportunities that may be presented to it. Blueberries may incur major unanticipated liabilities or expenses. Blueberries can provide no assurance that it will be able to obtain financing to meet the growth needs of Blueberries.

Foreign Sales

Blueberries' functional currency is denominated in Canadian dollars. Blueberries currently expects that sales will be denominated in Colombian pesos and may, in the future, have sales denominated in the currencies of additional countries in which it establishes sales offices. In addition, Blueberries incurs the majority of its operating expenses in Colombia Pesos. In the future, the proportion of Blueberries' sales that are international may increase. Such sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively impact the Company's business, financial condition and results of operations. Blueberries has not previously engaged in foreign currency hedging. If the Company decides to hedge its foreign currency exposure, it may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid markets. In addition, those activities may be limited in the protection they provide the Company from foreign currency fluctuations and can themselves result in losses.

Estimates or Judgments Relating to Critical Accounting Policies

The preparation of financial statements in conformity with International Financial Reporting Standards, or IFRS, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Blueberries bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided in the notes to the Blueberries Financial Statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. Blueberries' operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause Blueberries' operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the share price of the Company. Significant assumptions and estimates used in preparing the financial statements include those related to the credit quality of accounts receivable, income tax credits receivable, share based payments, impairment of non-financial assets, fair value of biological assets, as well as revenue and cost recognition.

Tax Risks

The Company will operate and will be subject to income tax and other forms of taxation (which are not based upon income) in multiple tax jurisdictions. Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates is also subject to change. Therefore, the Company's earnings may be impacted by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The Company may have exposure to greater than anticipated tax liabilities or expenses. The Company will be subject to income taxes and non-income taxes in a variety of jurisdictions and its tax structure is subject to review by both domestic and foreign taxation authorities and the determination of the Company's provision for income taxes and other tax liabilities will require significant judgment.

The Company will be subject to different taxes imposed by the Colombian government and any changes within such tax legal and regulatory framework may have an adverse effect on our financial results. All current tax legislation is a matter of public record and the Company will be unable to predict which additional legislation or amendments may be enacted.

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



DISCLOSURE OF INTERNAL CONTROLS

Management has established processes to provide sufficient knowledge to support representations that it has exercised reasonable diligence that (i) the financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of and for the periods presented in the financial statements, and (ii) the financial statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented.

The Company utilizes the Venture Issuer Basic Certificate, which certificate does not include representations related to the establishment and maintenance of disclosure controls and procedures ("DC&P") or internal control over financial reporting ("ICFR"), as defined in NI 52-109. In particular, the certifying officers do not make any representations related to the establishment and maintenance of:

- i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

NON-GAAP MEASURES

Certain financial measures in this document do not have a standardized meaning as prescribed by IFRS and therefore are considered non-GAAP measures. These measures may not be comparable to similar measures presented by other issuers. These measures have been described and presented in order to provide shareholders and potential investors with additional measures for analyzing our ability to generate funds to finance our operations and information regarding our liquidity. The additional information should not be considered in isolation or as a substitute for measures prepared in accordance with IFRS. The definition and reconciliation of each non-GAAP measure is presented in the Discussion of Operations and Liquidity and Capital Resources sections of this MD&A.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This MD&A contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). These statements relate to future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this MD&A speak only as of the date of this MD&A or as of the date specified in such statement. The following table outlines certain significant forward-looking statements contained in this MD&A and provides the material assumptions used to develop such forward-looking statements and material risk factors that could cause actual results to differ materially from the forward-looking statements.

Forward Looking Statements	Assumptions	Risk Factors
The Company will be able to continue its business activities.	The Company has anticipated all material costs and the operating activities of the Company, and such	COVID-19 caused closures and other unforeseen costs to the Company will arise; any particular

Blueberries Medical Corp.

Management's Discussion and Analysis

For the three months ended March 31, 2021

(All amounts in Canadian Dollars, unless otherwise stated)



Forward Looking Statements	Assumptions	Risk Factors
	costs and activities will be consistent with the Company's current expectations; the Company will be able to obtain equity funding when required.	operation cost increase or decrease from the date of the estimation; and due to COVID-19 capital markets not being favourable for funding resulting in the Company not being able to obtain financing when required or on acceptable terms.
The Company will be able to carry out anticipated business plans.	In the next twelve months, the operating activities of the Company will be consistent with the Company's current expectations; debt and equity markets, interest rates and other applicable economic conditions are favourable to the Company.	COVID-19 related uncertainty continuing; sufficient funds not being available; increases in costs, the Company may be unable to retain key personnel to develop or enhance its business, take advantage of future opportunity or respond to competitive pressures.
Management's outlook regarding future trends.	Financing will be available for the Company's future business, continuing development, and maintenance of operations.	COVID-19 situation and general economic conditions could adversely impact spending by the Company's clients, put downward pressure on prices which could adversely impact the business, financial condition or results of operations and the Company may be unable to retain personnel.

Inherent in forward-looking statements are risks, uncertainties and other factors beyond the Company's ability to predict or control. Please also make reference to those risk factors discussed further below. Readers are cautioned that the above chart does not contain an exhaustive list of the factors or assumptions that may affect the forward-looking statements, and that the assumptions underlying such statements may prove to be incorrect. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this MD&A.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements whether as a result of new information or future events or otherwise, except as may be required by law. If the Company does update one or more forward looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law.

May 31, 2021

"Facundo Garreton"

Facundo Garreton
Chairman and Chief Executive Officer

"Ian D. Atacan"

Ian D. Atacan, CPA, CMA
Chief Financial Officer

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated May 31, 2021.

Ian Atacan
Name of Director or Senior Officer

"Ilan Atacan"
Signature

Chief Financial Officer
Official Capacity

Issuer Details		For Quarter End	Date of Report YY/MM/DD
Name of Issuer		March 31, 2021	2021/05/31
Blueberries Medical Corp.			
Issuer Address			
885 West Georgia			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 3E8			
Contact Name		Contact Position	Contact Telephone No.
Ilan Atacan		CFO	(416) 562-3220
Contact Email Address		Web Site Address	
iatacan@blueberries		www.blueberriesmed.com	